Global Psychiatric Digital Biomarkers Market size is estimated to be USD 7.65 Billion in 2025 and is projected to reach USD 36.8 Billion in 2034. The market is anticipated to grow at a CAGR of 19.5%Â during the forecast period 2025 – 2034.
Psychiatric Digital Biomarkers Market: Growth Factors and Dynamics
Technological advancements in developing digital biomarkers and the high presence of market participants who manufacture them are the primary factors driving the growth of the global digital biomarkers market.
Moreover, the demand for digital biomarkers is expected to increase due to the increasing prevalence of chronic diseases, including cardiovascular diseases, diabetes, mental health disorders, neurodegenerative diseases, and chronic pain conditions.
In addition, these biomarkers are employed in the evaluation and diagnosis of neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease. Technologies such as digital cognitive evaluations, smartphone-based assessments, and wearable sensors can facilitate monitoring disease progression, motor symptoms, cognitive decline, and the response to interventions.
Therefore, it is anticipated that the digital biomarker market will experience growth and the demand for digital biomarkers will increase due to the increasing prevalence of Parkinson’s disease. For example, the Parkinson’s Foundation reported that nearly 90,000 individuals in the United States were diagnosed with Parkinson’s disease annually in 2022.
This is a substantial 50% increase from the previous estimated rate of 60,000 diagnoses per year. Moreover, digital voice biomarkers are currently being examined as a potential instrument for assessing and monitoring Parkinson’s disease (PD).
These biomarkers analyze speech characteristics and vocal patterns to identify changes that may indicate Parkinson ‘s-related motor and non-motor symptoms.
Additionally, it is anticipated that the digital biomarkers market will experience development due to an increase in the availability of digital biomarkers for neurological disorders. For example, Koneksa, the industry leader in developing and implementing digital biomarkers, offers digital biomarkers to patients with Parkinson’s disease.
This cloud-based software service (SaaS) is utilized to treat Parkinson’s disease. In addition, ActiGraph LLC, a biotechnology research company, offers ActiGraph wGT3X-BT, which is suitable for fall detection and gait analysis.
It is anticipated that the prevalence of chronic diseases, including cardiovascular disorders, respiratory diseases, and neurological diseases, will increase due to the growing geriatric population. Therefore, this factor is anticipated to increase the demand for digital biomarkers in the geriatric population and drive the market’s growth.
For instance, digital biomarkers are employed in the geriatric population to monitor or diagnose various diseases, including Alzheimer’s disease and dementia, gait disorders, falls and fall risk assessment, cardiovascular health, and various others.
Report Scope
| Feature of the Report | Details |
| Market Size in 2025 | USD 7.65 Billion |
| Projected Market Size in 2034 | USD 36.8 Billion |
| Market Size in 2024 | USD 5.78 Billion |
| CAGR Growth Rate | 19.5% CAGR |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Key Segment | By Type, Clinical Practice, End Use and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your research requirements. |
Psychiatric Digital Biomarkers Market: Recent Developments
- A MedTech leader based in Basel, Switzerland, Indivi, partnered with Biogen in March 2024 to advance digital health innovations, specifically emphasizing the development of digital biomarkers for Parkinson’s disease. Biogen licensed its smartphone-based digital biomarker platform, KonectomTM, to Indivi as a substantial component of this agreement.
- Empatica, a digital health and AI company, announced in November 2024 that its Empatica Health Monitoring Platform had been granted 510(k) clearance by the US FDA for two additional digital biomarkers: pulse and respiratory rate. This approval expands the platform to include six FDA-cleared digital biomarkers, establishing it as one of the most prominent clinical trial solutions.
- Koneksa, a digital biomarker startup, secured USD 45 million in a Series C funding round in February 2022. The funds are intended to be used to enhance the science team and expand the platform, with a particular emphasis on developing the digital biomarker platform and enhancing the clinical data integration tools.
List of the prominent players in the Psychiatric Digital Biomarkers Market:
- Canary Speech Inc
- Sonde Health Inc. (Puretech Health Plc)
- Koneksa Health Inc.
- Empatica Inc.
- VivoSense Inc.
- IXICO Plc
- Neurotrack Technologies Inc.
- Winterlight Labs
- Aural Analytics Inc. (Linus Health)
- Others
The Psychiatric Digital Biomarkers Market is segmented as follows:
By Type
- Wearable
- Mobile based Applications
- Sensors
- Other Type
By Clinical Practice
- Diagnostic Psychiatric Digital Biomarkers
- Monitoring Psychiatric Digital Biomarkers
- Predictive and Prognostic Psychiatric Digital Biomarkers
- Other Clinical Practice
By End Use
- Healthcare Companies
- Healthcare Providers
- Payers
- Other End Use
Regional Coverage:
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- France
- U.K.
- Russia
- Italy
- Spain
- Netherlands
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Taiwan
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America